文献速递流行病学与生物统计临床试验与 GCP

无症状非妊娠青少年和成人HIV感染筛查:美国预防服务工作组更新证据报告与系统综述

Screening for HIV Infection in Asymptomatic, Nonpregnant Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
PubMed 文献 · JAMA · 2019-01-01

本系统综述为美国预防服务工作组(USPSTF)更新2012年HIV筛查证据,纳入18项新研究(N=266563)及11项既往研究(N=218542)。未发现直接比较筛查与不筛查对临床结局或危害影响的研究,也未发现替代筛查策略检出率的研究。新证据显示CD4细胞计数大于500/mm3时启动抗逆转录病毒治疗(ART)可降低死亡、艾滋病定义事件或严重非艾滋病事件复合结局风险,并持续降低HIV传播风险,但某些ART方案可能与长期危害风险增加相关。

要点

  • 无直接证据评估HIV筛查与不筛查对临床结局或危害的影响,也无替代筛查策略检出率证据。
  • CD4细胞计数大于500/mm3时启动ART与复合结局风险降低相关(RR 0.44和0.57)。
  • 早期ART与5.5年时HIV传播风险持续降低相关(RR 0.07)。

核心结论

  • 在非妊娠青少年和成人中,无直接证据评估HIV筛查与不筛查的临床获益和危害,也无重复或替代筛查策略的检出率证据。
  • 新证据将ART的有效性扩展至CD4细胞计数大于500/mm3的无症状个体,并显示在较长随访中持续降低HIV传播风险,尽管某些ART方案可能与长期危害风险增加相关。

研究设计与样本

  • 为美国预防服务工作组(USPSTF)更新的系统综述,检索Ovid MEDLINE、Cochrane对照试验中心注册库和Cochrane系统评价数据库2012年至2018年6月,监测至2019年1月。
  • 纳入非妊娠12岁及以上个体中比较筛查与不筛查、替代筛查策略、早期与延迟启动ART及ART长期危害的随机临床试验(RCT)和对照观察性研究。
  • 纳入18项新研究(5项RCT、11项队列研究、2项系统综述;N=266563),并沿用既往USPSTF报告的11项研究(2项RCT、9项队列研究;N=218542)。
  • 一名研究者提取数据,第二名研究者核对准确性;两名研究者独立评定研究质量。

主要发现

  • 无研究直接评估HIV筛查与不筛查对临床结局或危害的影响,也无研究评估替代筛查策略的检出率。
  • 两项新识别的RCT(完全或部分在低资源地区开展)发现CD4细胞计数大于500/mm3时启动ART与死亡、艾滋病定义事件或严重非艾滋病事件复合结局风险降低相关(RR 0.44 [95% CI, 0.31-0.63] 和 RR 0.57 [95% CI, 0.35-0.95]),结果与一项大型观察性研究一致。
  • 早期ART与心血管事件风险增加无关。
  • 早期启动ART与5.5年时HIV传播风险持续降低相关(关联传播RR 0.07 [95% CI, 0.02-0.22])。
  • 关于阿巴卡韦使用与心血管事件风险关联的新证据不一致;某些抗逆转录病毒方案与长期神经精神、肾脏、肝脏和骨骼不良事件风险增加相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 无研究直接评估HIV筛查与不筛查对临床结局或危害的影响,也无研究评估重复或替代筛查策略的检出率。
  • 关于阿巴卡韦使用与心血管事件风险关联的新证据不一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Untreated HIV infection can result in significant morbidity, mortality, and HIV transmission. A 2012 review for the US Preventive Services Task Force (USPSTF) found antiretroviral therapy (ART) associated with improved clinical outcomes and decreased transmission risk in persons with CD4 cell counts less than 500/mm3. OBJECTIVE: To update the 2012 review on HIV screening to inform the USPSTF. DATA SOURCES: Ovid MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews from 2012 to June 2018, with surveillance through January 2019. STUDY SELECTION: Nonpregnant individuals 12 years and older; randomized clinical trials (RCTs) and controlled observational studies of screening vs no screening, alternative screening strategies, earlier vs later initiation of ART, and long-term harms of ART. DATA EXTRACTION AND SYNTHESIS: One investigator abstracted data; a second checked accuracy. Two investigators independently rated study quality. MAIN OUTCOMES AND MEASURES: Mortality, AIDS events, quality of life, function, and HIV transmission; harms of screening and long-term (≥2 years) harms of ART; screening yield. RESULTS: Eighteen new studies (5 RCTs, 11 cohort studies, and 2 systematic reviews; N = 266 563) were included, and 11 studies (2 RCTs and 9 cohort studies; N = 218 542) were carried forward from the prior USPSTF report. No study directly evaluated effects of HIV screening vs no screening on clinical outcomes or harms, or the yield of alternative screening strategies. Two newly identified RCTs conducted completely or partially in low-resource settings found ART initiation at CD4 cell counts greater than 500/mm3 associated with lower risk of a composite outcome of mortality, AIDS-defining events, or serious non-AIDS events (relative risk [RR], 0.44 [95% CI, 0.31-0.63] and RR, 0.57 [95% CI, 0.35-0.95]); results were consistent with those from a large observational study. Early ART was not associated with increased risk of cardiovascular events. Early ART initiation was associated with sustained reduction in risk of HIV transmission at 5.5 years (RR, 0.07 [95% CI, 0.02-0.22] for linked transmission). New evidence regarding the association between abacavir use and risk of cardiovascular events was inconsistent. Certain antiretroviral regimens were associated with increased risk of long-term neuropsychiatric, renal, hepatic, and bone adverse events. CONCLUSIONS AND RELEVANCE: In nonpregnant adolescents and adults there was no direct evidence on the clinical benefits and harms of screening for HIV infections vs no screening, or the yield of repeat or alternative screening strategies. New evidence extends effectiveness of ART to asymptomatic individuals with CD4 cell counts greater than 500/mm3 and shows sustained reduction in risk of HIV transmission at longer-term follow-up, although certain ART regimens may be associated with increased risk of long-term harms.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Chou R, Dana T, Grusing S, et al. Screening for HIV Infection in Asymptomatic, Nonpregnant Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2019. PMID: 31184705. doi:10.1001/jama.2019.2592

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。